^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MHB036C

    i
    Other names: MHB036C, ZG157, MHB-036C, ZG-157
    Associations

    News

    Trials
    Company:
    Minghui Pharma
    Drug class:
    Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    16d
    A Study of MHB036C for Advanced Solid Tumor (clinicaltrials.gov)
    P1/2, N=200, Active, not recruiting, Minghui Pharmaceutical (Hangzhou) Ltd | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Aug 2024 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    MHB036C
    17d
    A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P2, N=210, Recruiting, Minghui Pharmaceutical (Hangzhou) Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MHB036C
    17d
    A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer (clinicaltrials.gov)
    P1/2, N=300, Recruiting, Minghui Pharmaceutical (Hangzhou) Ltd
    New P1/2 trial
    |
    carboplatin • Ivesa (firmonertinib) • MHB036C
    4ms
    A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P2, N=210, Not yet recruiting, Minghui Pharmaceutical (Hangzhou) Ltd
    New P2 trial
    |
    MHB036C
    almost3years
    Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=400, Not yet recruiting, Minghui Pharmaceutical Pty Ltd
    New P1/2 trial • Metastases
    |
    TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    HER-2 positive • HR positive • HER-2 expression • TROP2 expression • PGR expression
    |
    MHB036C